We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Common Variant Modifiers for Syndromic Heart Condition Located

By LabMedica International staff writers
Posted on 09 Jan 2020
DiGeorge syndrome, also known as 22q11. More...
2 deletion syndrome, is a syndrome caused by the deletion of a small segment of chromosome 22. While the symptoms can vary, they often include congenital heart problems, specific facial features, frequent infections, developmental delay, learning problems and cleft palate.

DiGeorge syndrome is typically due to the deletion of 30 to 40 genes in the middle of chromosome 22 at a location known as 22q11.2. About 90% of cases occur due to a new mutation during early development, while 10% are inherited from a person's parents. It is autosomal dominant, meaning that only one affected chromosome is needed for the condition to occur. Diagnosis is suspected based on the symptoms and confirmed by genetic testing.

A large team of scientists working with those at the Albert Einstein College of Medicine (Bronx, NY, USA) searched for rare disease modifiers using whole-genome sequence data for more than 1,000 individuals with 22q11.2 deletion syndrome (22q11.2DS), before doing common variant searches with case-control data and genome-wide association meta-analyses. Together, their analyses led to a block of common variants in and around CRKL, including a single nucleotide polymorphism (SNP) influencing the expression of that enzyme-coding proto-oncogene. While the individuals all had 22q11.2DS, more than 40% had conotruncal heart defects and almost 56% had any type of congenital heart diagnosis, while 469 individuals were not affected by heart disease or other conditions considered.

Bernice E. Morrow, a professor of Genetics and senior author of the study, said, “Complete sequence data indicate that this association was not driven by rare variants individually or jointly in the same region, suggesting that associated common variants are among the top causal variants.”

The author concluded that their findings suggest that variance in conotruncal type defects (CTD) penetrance in the 22q11.2DS population can be explained in part by variants affecting CRKL expression. Haploinsufficiency of this region alone is associated with conotruncal defects, and when taken together with mouse genetic studies, the results presented implicate, most plausibly, CRKL as a possible target of non-coding putative regulatory variants. The study was published on December 20, 2019 in the American Journal of Human Genetics.

Related Links:
Albert Einstein College of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automatic CLIA Analyzer
Shine i6000
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The screening algorithm incorporates two plasma biomarkers: amyloid-beta ratio and p-tau217, which together help indicate brain amyloid burden (Image Credit: Shutterstock)

Algorithm Uses Blood Biomarkers to Improve Alzheimer’s Trial Screening

Alzheimer’s disease is a progressive neurodegenerative disorder that causes memory loss and functional decline. Screening cognitively healthy adults for prevention trials is slow and costly because many... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.